The U.S. nuclear medicine market was valued at approximately USD 6.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 15.6% from 2024 to 2032. Key drivers of this growth include increased demand for radiopharmaceuticals in oncology, cardiology, and neurology, heightened prevalence of chronic diseases, and advancements in diagnostic and therapeutic technologies. The demand for non-invasive diagnostic techniques such as PET and SPECT scans is rising, with PET expected to dominate the nuclear medicine procedures market. In 2023, the diagnostics segment generated about USD 4.5 billion, while the neurology application accounted for 30% of the market share. Hospitals are the primary end-users, with an expected market reach of USD 15 billion by 2032. Regional growth is particularly notable in East North Central and West South-Central areas. Major players in the market include Jubilant Pharma, Cardinal Health, Novartis, Lantheus, GE Healthcare, and Boston Scientific, among others, contributing to a competitive landscape driven by innovation and extensive product offerings.
Thu, 24 Oct 2024 13:31:59 GMT | Global Market Insights